Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines

Biochemical Journal

Volumn 373, Issue 1, 2003, Pages 25-32

  Nair, Venugopalan D ^a   Olanow, C Warren ^a   Sealfon, Stuart C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine agonist; G protein; Neuroprotection; Parkinson's disease; Signal transduction

Indexed keywords

CELLS; DISEASES; PROTEINS;

CLINICAL TRIALS;

BIOCHEMISTRY;

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BROMOCRIPTINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HYDROGEN PEROXIDE; LY 29004; MITOGEN ACTIVATED PROTEIN KINASE; PERGOLIDE; PHOSPHATIDYLINOSITOL 3 KINASE; UNCLASSIFIED DRUG; WORTMANNIN;

APOPTOSIS; ARTICLE; CELL LINE; CONCENTRATION RESPONSE; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 4-KINASE; ANIMALS; APOPTOSIS; BROMOCRIPTINE; CELL SURVIVAL; ENZYME ACTIVATION; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HYDROGEN PEROXIDE; KINETICS; MITOGEN-ACTIVATED PROTEIN KINASES; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PC12 CELLS; RATS; RECEPTORS, DOPAMINE D2; TUMOR CELLS, CULTURED;

EID: 0037668195     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20030017     Document Type: Article

References (42)

1. Jenner, P. and Olanow, C. W. (1998) Understanding cell death in Parkinson's disease. Ann. Neurol. 44, S72-S84
2. Honig, L. S. and Rosenberg, R. N. (2000) Apoptosis and neurologic disease. Am. J. Med. 108, 317-330
3. Mattson, M. (2000) Apoptasis in neurodegenerative disorders. Nat. Rev. Mol. Cell. Biol. 1, 120-129
4. Hartmann, A. and Hirsch, E. C. (2001) Parkinsan's disease. The apaptosis hypothesis revisited. Adv. Neurol. 86, 143-153
5. Eberhardt, O., Caelln, R. V., Kugler, S., Lindenau, J., Rathke-Hartlieb, S., Gerhardt, E., Haid, S., Isenmann, S., Gravel, C., Srinivasan, A. et al. (2000) Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinsan's disease. J. Neurosci. 20, 9126-9134
6. Lotharius, J. and O'Malley, K. L. (2000) The Parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers Intracellular dopamine oxidation. A novel mechanism of toxicity. J. Biol. Chem. 275, 38581-38588
7. Tatton, N. A. and Kish, S. J. (1997) In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77, 1037-1048
8. Olanow, C. W., Jenner, P. and Brooks, D. (1998) Dopamine agonists and neuroprotection in Parkinson's disease. Ann. Neurol. 44, S167-S174
9. Calne, D. B., Burton, K., Beckman, J. and Martin, W. R. (1984) Dopamine agonists in Parkinson's disease. Can. J. Neurol. Sci. 11, 221-224
10. Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E. and Lang, A. E. (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J Med. 342, 1484-1491
11. Group, P. S. (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. J. Am. Med Assoc. 234, 1931-1938
12. Brunt, E. R., Brooks, D. J., Korczyn, A. D., Montastruc, J. L. and Stocchi, F. (2002) A six-month multicentre, double-blind, bramocriptine-cantrolled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dapa. J. Neural Transm. 109, 489-502
13. Takashima, H., Tsujihata, M., Kishikawa, M. and Freed, W. J. (1999) Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors. Exp. Neurol. 159, 98-104
14. Iida, M., Miyazaki, I., Tanaka, K., Kabuto, H., Iwata-Ichikawa, E. and Ogawa, N. (1999) Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res. 828, 51-59
15. Greene, L. A. and Tischler, A. S. (1976) Establishment of a noradrenergic clonal line of rat adrenal pheochromacytoma cells which respond to nerve growth factor. Proc. Natl. Acad. Sci. U.S.A. 73, 2424-2428
16. Son, J. H., Chun, H. S., Joh, T. H., Cho, S., Conti, B. and Lee, J. W. (1999) Neuroprotection and neuronal differentiation studies using substantia nigra dopaminergic cells derived from transgenic mouse embryos. J. Neurosci. 19, 10-20
17. Shearman, M., Ragan, C. and Iversen, L. (1994) Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of beta-amyloid-mediated cell death. Proc. Natl. Acad. Sci. U.S.A. 91, 1470-1474
18. Mossman, T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63
19. Grandy, D. K., Marchionni, M. A., Makam, H., Stofko, R. E., Alfano, M., Frothingham, L., Fischer, J. B., Burke-Howie, K. J., Bunzow, J. R. and Server, A. C. (1989) Cloning of the cDNA and gene for a human D2 dopamine receptor. Proc. Natl. Acad. Sci. U.S.A 86, 9762-9766
20. Cardeaux, Y., Nickolls, S. A., Flood, L. A., Graber, S. G. and Strange; P. G. (2001) Agonist regulation of D(2) dopamine receptor/G protein interaction. Evidence for agonist selection of G protein subtype. J. Biol. Chem. 276, 28667-28675
21. Blum, D., Torch, S, Lambeng, N., Nissou, M., Benabid, A. L., Sadoul, R. and Verna, J. M. (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Progr. Neurobiol. 65, 135-172
22. Hartmann, A., Hunot, S., Michel, P. P., Muriel, M.-P., Vyas, S., Faucheux, B. A., Mouatt-Prigent, A., Turmel, H., Srinivasan, A., Ruberg, M. et al. (2000) Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 97, 2875-2880
23. Anastasiadis, P. Z., Jiang, H., Bezin, L., Kuhn, D. M. and Levine, R. A. (2001) Tetrahydrobiapterin enhances apoptotic PC12 cell death following withdrawal of trophic support. J. Biol. Chem. 276, 9050-9058
24. Chun, H. S., Gibson, G. E., DeGiorgia, L. A., Zhang, H., Kidd, V. J. and Son, J. H. (2001) Dopaminergic cell death induced by MPP(+), oxidant and specific neurotoxicants shares the common molecular mechanism. J. Neurochem. 76, 1010-1021
25. Sawada, H., Ibi, M., Kihara, T., Urushitani, M., Akaike, A., Kimura, J. and Shimohama, S. (1998) Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann. Neurol. 44, 110-119
26. Ishige, K., Chen, Q., Sagara, Y. and Schubert, D. (2001) The activation of dapamine D4 receptors inhibits oxidative stress-induced nerve cell death. J. Neurosci. 21, 6069-6076
27. Fukuda, T., Watabe, K. and Tanaka, J. (1996) Effects of bromacriptine and/or L-DOPA on neurons in substantia nigra of MPTP-treated C57BL/6 mice. Brain Res. 728, 274-276
28. Tanaka, M., Sotamatsu, A., Yashida, T. and Hirai, S. (1995) Inhibitory effects of bromocriptine on phospholipid peroxidation induced by dopa and iron. Neurosci. Lett. 183, 116-119
29. Le, W. D., Jankovic, J., Xie, W. and Appel, S. H. (2000) Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J. Neural Transm. 107, 1165-1173
30. Sethy, V. H., Wu, H., Oostveen, J. A. and Hall, E. D. (1997) Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats. Brain Res. 754, 181-186
31. Zou, L, Xu, J., Jankovic, J., He, Y., Appel, S. H. and Le, W. (2000) Pramipexole inhibits lipid peraxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci. Lett. 281, 167-170
32. Kitamura, Y., Kosaka, T., Kakimura, J. I., Matsuoka, Y., Kohno, Y., Nomura, Y. and Taniguchi, T. (1998) Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apogtotic death in human neuroblastoma SH-SY5Y cells. Mol. Pharmacol 54, 1046-1054
33. Kakimura, J., Kitamura, Y., Takata, K., Kohno, Y., Nomura, Y. and Taniguchi, T. (2001) Release and aggregation of cytochrome c and α-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur. J. Pharmacol. 417, 59-67
34. Cassarino, D. S., Fall, C. P., Smith, T. S. and Bennett, J. P., Jr. (1998) Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J. Neurochem. 71, 295-301
35. Zou, L., Jankovic, J., Rowe, D. B., Xie, W., Appel, S. H. and Le, W. (1999) Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci. 64, 1275-1285
36. 2 and 6-hydroxydopamine. Mov. Disord. 13, 661-667
37. Mitchell, R., McCulloch, D., Lutz, E., Johnson, M., MacKenzie, C., Fennell, M., Fink, G., Zhou, W. and Sealfon, S. C. (1998) Rhodopsin-family receptors associate with small G proteins to activate phospholipase D. Nature (London) 392, 411-414
38. + exchange. Nature (London) 392, 626-630
39. Cao, W., Luttrell, L. M., Medvedev, A. V., Pierce, K. L., Daniel, K. W., Dixon, T. M., Lefkowitz, R. J. and Collins, S. (2000) Direct binding of activated c-Src to the beta 3-adrenergic receptor is required for MAP kinase activation. J. Biol. Chem. 275, 38131-38134
40. Kenakin, T. (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol. Sci. 16, 232-238
41. Han, B. H. and Holtzman, D. M. (2000) BDNF protects the neonatal brain from hypoxic-ischemic injury in vivo via the ERK pathway. J. Neurosci. 20, 5775-5781
42. Kihara, T., Shimohama, S., Sawada, H., Honda, K., Nakamizo, T., Kanki, R., Yamashita, H. and Akaike, A. (2002) Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascade. J. Neurosci Res. 70, 274-282